研究者学術情報データベース

ハヤシヨシヒロ
林嘉宏
HAYASHI YOSHIHIRO

所属薬学部薬学科

職名教授

論文
1.	2023/04	Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders. │ Cancer science │ (共著)
2.	2023/03	The early neutrophil-committed progenitors aberrantly differentiate into immunoregulatory monocytes during emergency myelopoiesis. │ Cell reports │ 42 (3),112165 (共著)
3.	2023/01	A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression. │ Nature communications │ 14 (1),23 (共著)
4.	2023	ミトコンドリア異常による骨髄異形成症候群発症機構 │ 『実験医学』 │ (共著)
5.	2022/05	Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective. │ Leukemia │ 36 (5),1203-1214 (共著)
6.	2022/02	Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. │ Cancer letters │ 526,273-283 (共著)
7.	2022/01	Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes. │ Cancer discovery │ 12 (1),250-269 (共著)
8.	2022	ミトコンドリア異常による骨髄異形成症候群の発症機序 │ 『血液内科』 │ (共著)
9.	2021/08	Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. │ Molecular cancer therapeutics │ 20 (8),1412-1421 (共著)
10.	2021/03	Conversion of neutrophils into atypical Ly6G⁺ SiglecF⁺ immune cells with neurosupportive potential in olfactory neuroepithelium. │ Journal of leukocyte biology │ 109 (3),481-496 (共著)
11.	2021	骨髄線維化を伴うMDS（MDS-F）の病態と鑑別すべき疾患 │ 『血液内科』 │ (単著)
12.	2020/07	C/EBPβ isoforms sequentially regulate regenerating mouse hematopoietic stem/progenitor cells. │ Blood advances │ 4 (14),3343-3356 (共著)
13.	2020/05	Gene rearrangements of MLL and RUNX1 sporadically occur in normal CD34+ cells under cytokine stimulation. │ Cancer science │ 111 (5),1851-1855 (共著)
14.	2020/05	Rare Neurologic Disease-Associated Mutations of AIMP1 are Related with Inhibitory Neuronal Differentiation Which is Reversed by Ibuprofen. │ Medicines (Basel, Switzerland) │ 7 (5) (共著)
15.	2020	造血器腫瘍におけるHIF1A/ARNTシグナル経路とがん幹細胞制御 │ 『医学のあゆみ』 │ (共著)
16.	2019/11	SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. │ Leukemia │ 33 (11),2585-2598 (共著)
17.	2019/05	Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. │ Cancer science │ 110 (5),1510-1517 (共著)
18.	2019/04	NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis. │ Blood advances │ 3 (7),1047-1060 (共著)
19.	2019/02	C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cells. │ Blood advances │ 3 (3),476-488 (共著)
20.	2019	骨髄異形成症候群の病態におけるHIF1Aの役割 │ 『臨床血液』 │ 60 (7),818-823 (単著)
21.	2018/11	Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. │ Cancer discovery │ 8 (11),1438-1457 (共著)
22.	2018/07	Setd2 regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongation. │ Haematologica │ 103 (7),1110-1123 (共著)
23.	2018/04	SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia. │ Leukemia │ 32 (4),890-899 (共著)
24.	2018/01	Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models. │ Haematologica │ 103 (1),40-50 (共著)
25.	2017/11	HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. │ Haematologica │ 102 (11),1956-1968 (共著)
26.	2017/08	Myeloid neoplasms with germ line RUNX1 mutation. │ International journal of hematology │ 106 (2),183-188 (共著)
27.	2017	RNAスプライシング異常が骨髄異形成を起こす機序 │ 『血液内科』 │ (共著)
28.	2014/08	Parathyroid hormone enhances hematopoietic expansion via upregulation of cadherin-11 in bone marrow mesenchymal stromal cells. │ Stem cells (Dayton, Ohio) │ 32 (8),2245-55 (共著)
29.	2014/06	Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. │ Nature communications │ 5,4177 (共著)
30.	2014/03	CCAAT/enhancer-binding protein β expressed by bone marrow mesenchymal stromal cells regulates early B-cell lymphopoiesis. │ Stem cells (Dayton, Ohio) │ 32 (3),730-40 (共著)
31.	2014/03	Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal. │ Blood │ 123 (11),1729-38 (共著)
32.	2013/03	C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion. │ Leukemia │ 27 (3),619-28 (共著)
33.	2013	慢性期CMLと類白血病反応に共通する分子機構 │ 『血液内科』 │ (共著)
34.	2012/11	C/EBPβ is involved in the amplification of early granulocyte precursors during candidemia-induced "emergency" granulopoiesis. │ Journal of immunology │ 189 (9),4546-55 (共著)
35.	2011/12	Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor. │ Cancer letters │ 312 (1),91-100 (共著)
36.	2011/12	Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. │ Cancer letters │ 312 (2),228-34 (共著)
37.	2011/11	AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. │ Blood cancer journal │ 1 (11),e43 (共著)
38.	2011/03	Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. │ Cancer science │ 102 (3),591-6 (共著)